deltatrials
Completed PHASE2 INTERVENTIONAL 8-arm NCT03276143

FactOr XIa inhibiTion for the pRevention of venOus Thromboembolism in Patients Undergoing Total Knee Arthroplasty (FOXTROT)

A Randomized, Active-comparator-controlled, Multicenter Study to Assess the Safety and Efficacy of Different Doses of BAY1213790 for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Primary Total Knee Arthroplasty, Open-label to Treatment and Observer-blinded to BAY1213790 Doses

Sponsor: Bayer

Conditions Knee Arthroplasty, Total
Interventions Apixaban BAY1213790 Enoxaparin
Updated 19 times since 2017 Last updated: Feb 28, 2020 Started: Sep 21, 2017 Primary completion: Aug 20, 2018 Completion: Jan 2, 2019
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03276143, this PHASE2 trial focuses on Knee Arthroplasty, Total and remains completed. Sponsored by Bayer, it has been updated 19 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Feb 2018 · 2 months · monthly snapshot~Feb 2018 – ~Apr 2018 · 59 days · monthly snapshot~Apr 2018 – ~May 2018 · 30 days · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Sep 2018 · 31 days · monthly snapshot~Sep 2018 – ~Oct 2018 · 30 days · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~Apr 2020 · 14 months · monthly snapshot~Apr 2020 – ~Jan 2021 · 9 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  5. Apr 2020 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 14 earlier versions

  1. Feb 2019 — Apr 2020 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  2. Jan 2019 — Feb 2019 [monthly]

    Active Not Recruiting PHASE2

  3. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  4. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Sep 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Aug 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  8. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE2

  9. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  10. May 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  11. Apr 2018 — May 2018 [monthly]

    Recruiting PHASE2

  12. Feb 2018 — Apr 2018 [monthly]

    Recruiting PHASE2

  13. Dec 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

  14. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bayer
Data source: Bayer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alcabideche, Portugal , Alcorcón, Spain , Aveiro, Portugal , Barcelona, Spain , Bialystok, Poland , Brno, Czechia , Cape Town, South Africa , Cherkasy, Ukraine , Haifa, Israel , Ivano-Frankivsk, Ukraine and 37 more locations